A Randomized, Phase II Trial Evaluating the Efficacy and Safety of Lenalidomide, Bortezomib and Dexamethasone (RVD) With or Without Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma

Trial Profile

A Randomized, Phase II Trial Evaluating the Efficacy and Safety of Lenalidomide, Bortezomib and Dexamethasone (RVD) With or Without Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2016

At a glance

  • Drugs Panobinostat (Primary) ; Bortezomib; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms PANORAMA4
  • Sponsors Novartis
  • Most Recent Events

    • 07 Oct 2016 Planned End Date changed from 1 Jun 2021 to 1 Feb 2021.
    • 07 Oct 2016 Planned primary completion date changed from 1 Jun 2021 to 1 Feb 2021.
    • 02 Sep 2016 Planned End Date changed from 1 May 2021 to 1 Jun 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top